WELLS FARGO & COMPANY/MN - OVID THERAPEUTICS INC ownership

OVID THERAPEUTICS INC's ticker is OVID and the CUSIP is 690469101. A total of 65 filers reported holding OVID THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
WELLS FARGO & COMPANY/MN ownership history of OVID THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,708,669
+15.5%
444,966
-1.3%
0.00%
Q2 2023$1,479,172
+33.1%
450,967
+4.7%
0.00%
Q1 2023$1,111,106
+39.2%
430,661
+0.4%
0.00%
Q4 2022$798,230
-0.2%
429,156
-1.3%
0.00%
Q3 2022$800,000
-13.9%
434,820
+0.7%
0.00%
Q2 2022$929,000
-31.9%
432,001
-0.7%
0.00%
Q1 2022$1,365,000
-6.0%
434,853
-3.9%
0.00%
Q4 2021$1,452,000
-4.8%
452,367
-0.4%
0.00%
Q3 2021$1,526,000
-14.0%
454,117
+0.1%
0.00%
Q2 2021$1,774,000
-3.7%
453,617
-1.0%
0.00%
Q1 2021$1,842,000
+44.6%
458,285
-16.9%
0.00%
Q4 2020$1,274,000
-58.5%
551,759
+3.1%
0.00%
-100.0%
Q3 2020$3,071,000
-19.9%
535,086
+2.8%
0.00%0.0%
Q2 2020$3,836,000
+162.7%
520,435
+6.3%
0.00%0.0%
Q1 2020$1,460,000
-25.7%
489,821
+3.4%
0.00%0.0%
Q4 2019$1,966,000
+43.9%
473,633
+12.3%
0.00%
Q3 2019$1,366,000
+66.8%
421,700
-4.7%
0.00%
Q2 2019$819,000
+47.3%
442,604
+41.0%
0.00%
Q1 2019$556,000
+3170.6%
313,986
+4451.2%
0.00%
Q4 2018$17,000
-56.4%
6,899
-0.7%
0.00%
Q3 2018$39,000
-23.5%
6,947
+6.6%
0.00%
Q2 2018$51,000
+6.2%
6,514
-4.7%
0.00%
Q1 2018$48,000
+500.0%
6,838
+771.1%
0.00%
Q4 2017$8,000
+166.7%
785
+123.0%
0.00%
Q3 2017$3,0003520.00%
Other shareholders
OVID THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
TLS Advisors LLC 1,319,679$4,32918.57%
Madison Avenue Partners, LP 3,307,605$10,848,9432.37%
CHI Advisors LLC 864,822$2,836,6160.86%
Rubric Capital Management LP 5,445,910$17,862,5850.76%
BVF INC/IL 6,851,051$22,471,4470.63%
EcoR1 Capital, LLC 6,117,400$20,065,0720.49%
Artal Group S.A. 2,500,000$8,2000.25%
Tejara Capital Ltd 112,591$369,2980.18%
DCF Advisers, LLC 64,764$212,4260.11%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 801,152$2,627,7790.06%
View complete list of OVID THERAPEUTICS INC shareholders